Certainty in Testing Times
ProtonDx is a technology spin-out from Imperial College London founded in 2020.
ProtonDx was established in 2020 to commercialise multi-disciplinary research from Imperial College London to deliver rapid, accurate, portable, and low-cost diagnostics available worldwide.
Founded from the lab of Professor Pantelis Georgiou, its core technology builds on several years of innovative research in diagnostics and collaboration between engineering, medicine and molecular biology to deliver cutting edge molecular tests which can be used at the point-of-need.
The research team developed technology to identify diseases which impact low- and middle-income countries.
Bringing accurate tests to low resource environments has resulted in clinical validations for dengue in Taiwan in 2018, and malaria in Ghana in 2019. The resulting technology has been successfully tested for identifying antimicrobial resistance infection in the UK.
Cutting-edge electronics, molecular biology, and machine learning in a portable device potentially enables new methods to identify multiple pathogens using highly sensitive LAMP technology.
The innovative lab-on-a-chip technology has received awards including the 2020 IEEE CASS COVID-19 Entrepreneur’s award, the IEEE Sensors Technical Achievement award, IET Mike Sergeant Achievement Medal, Rosetrees Trust Interdisciplinary Prize, Wellcome Trust Innovator Award, two Imperial Techcelerate Awards, MedTech SuperConnector Award, and various other IEEE awards.
Develop ultra-rapid, extremely precise, molecular testing for everyone at the point-of-need.
Our ambition is to ensure tests can be conducted quickly, accurately and cost-effectively, wherever and whenever they are needed by societies throughout the world so that all can benefit from advances in technology.
The technology that makes ProtonDx possible is the result of years of research and development by a multi-disciplinary team of engineers, micro-biologists and medical specialists at Imperial College London.
With more than 30 years of healthcare and financial experience, he served as CEO of Equinox Funds and Chairman of Equinox Funds Trust, leading the firm’s growth from a commodity pool operator to an alternative investment asset manager with more than $2B in AUM. He has served in management roles with large, established companies, such as Bristol-Myers Squibb, and fast-growing, venture-funded organizations, such as Beansprout Networks. He was Senior Managing Director with The Hermes Group, a merchant banking and corporate advisory firm as well as general manager and vice president of Quintiles (acquirer of Beansprout), a $2 billion pharmaceutical services firm. Mr Enck holds a BS degree in Natural Sciences from St. John's University, Collegeville, MN and an MBA in Management from the University of St. Thomas, St. Paul, MN. Mr Enck serves on the Board of Trustees of the Chi Chi Rodriguez Youth Foundation, and as Chairman of US Gold Opportunity Fund.
Professor Pantelis Georgiou is a co-founder and CEO of ProtonDx, he currently holds the position of Professor of Biomedical Electronics at Imperial College London. Prof. Pantelis Georgiou graduated with a 1st Class Honours MEng Degree in Electrical and Electronic Engineering and PhD degree Imperial College London. He heads the Bio-inspired Metabolic and Infection Technology Laboratory in the Centre for Bio-Inspired Technology; a multi-disciplinary group that invents, develops and demonstrates advanced micro-devices to meet global challenges in biomedical science and healthcare. His research includes applications Lab-on-Chip technology for genomics and diagnostics targeted towards infectious disease and cancer. He has received the IET Mike Sergeant Medal, the IEEE Sensors Council Technical Achievement Award, and has been appointed as an IEEE Distinguished lecturer in circuits and systems. He has authored over 350 peer-reviewed publications related to healthcare technology, and has successfully secured over £10 million in healthcare related research funding.
Dr. Jesus Rodriguez-Manzano is a co-founder and CSO officer of PDx. He received a BSc in Biological Sciences, an MSc in Advanced Microbiology and a PhD in Biotechnology and Environmental Microbiology from the University of Barcelona. After post-doctoral positions in the Division of Chemistry and Chemical Engineering at the California Institute of Technology (Caltech) and in the Department of Electrical and Electronic Engineering at Imperial College London, he moved to the Department of Infectious Disease as a non-clinical Lecturer in Antimicrobial Resistance and Infectious Diseases in the Faculty of Medicine. Dr Rodriguez Manzano has a strong interdisciplinary background in microbiology, molecular biology and bioengineering, and his research interest includes the development of point-of-care technologies and novel molecular methods for diagnosis of infectious diseases and antimicrobial resistance, with particular interest in low- and middle-income countries. He is the author of over 60 scientific publications and 10 international patent applications with over 2,000 citations.
Dr. Nicolas Moser is a co-founder and CTO of PDx. He earned an MSc at Imperial College London with distinction and received the Hertha Ayrton Centenary Prize (best MSc project) and the MSc Analogue and Digital Integrated Circuit Design Outstanding Achievement Prize (highest ranking MSc student). He was awarded an EPSRC PhD Scholarship with the High Performance Embedded and Distributed Systems (HiPEDS) Centre for Doctoral Training (CDT) and pursued a PhD at the Centre for Bio-Inspired Technology, Imperial College London, where he developed new methods for microchip-based ion imaging. At the end of his PhD, he was awarded the EPSRC postdoctoral fellowship to pursue point-of-care devices towards rapid diagnosis of infectious diseases. He has pursued several entrepreneurial programmes including the Imperial College Techcelerate programme and the MedTech SuperConnector. He received the best poster at the All-You-Can-Innovate conference and the CASS COVID-19 Entrepreneur Award. He is the author of 39 publications and 2 patents.
An internationally acknowledged spine and scoliosis surgeon, successful investor and entrepreneur, Dr. Antonacci is board certified by the American Board of Orthopedic Surgery, a diplomate of the National Board of Medical Examiners, Fellow of the American Academy of Orthopedic Surgery, Fellow of the American College of Surgeons, Fellow of the Scoliosis Research Society, Fellow of the Cervical Spine Research Society and active member of the North American Spine Society.
Dr. Antonacci has extensive surgical experience in adults and children with spinal scoliosis. He is the developer and pioneer of anterior scoliosis correction (ASC) surgery for scoliosis, the most advanced surgical treatment for correcting scoliosis. ASC replaces metal rod fusion surgery and gives the patient the ability to continue with full sports, active life and flexibility in under two months.
Dr Antonacci graduated with a BS from Georgetown University before studying for MD in its School of Medicine. He has a residency in Orthopaedic Surgery at Baylor College of Medicine and a Fellowship at the Spinal Surgery at Jackson Memorial Hospital and is Lead Surgeon and Founder at the Institute Spine & Scoliosis.
CEO Professor Pantelis Georgiou explains the technology in a talk to Friends of Imperial College on Youtube
Some of the academic papers relating to the development of the technology:
A Handheld Point-of-Care System for Rapid Detection of SARS-CoV-2 in under 20 Minutes. ACS Central Science. 2021. 7 (2); 307-31.
Rapid Detection of Mobilized Colistin Resistance using a Nucleic Acid Based Lab-on-a-Chip Diagnostic System. Scientific Reports. 2020. 2020 May;10:8448.
Quantitative and rapid Plasmodium falciparum malaria diagnosis and artemisinin-resistance detection using a CMOS Lab-on-Chip platform.Biosensors and Bioelectronics. 2019 Dec 1;145:111678.
Framework for DNA Quantification and Outlier Detection Using Multidimensional Standard Curves.Analytical Chemistry. 2019 May 6;91(11);7426-7434.
Simultaneous Single-Channel Multiplexing and Quantification of Carbapenem-Resistant Genes Using Multidimensional Standard Curves.Analytical Chemistry. 2019 Jan 9;91(3);2013-2020.
A 12.8 k Current-Mode Velocity-Saturation ISFET Array for On-Chip Real-Time DNA Detection.IEEE Transactions on Biomedical Circuits and Systems. 2018 Oct;12(5):1202-1214.
A Scalable ISFET Sensing and Memory Array With Sensor Auto-Calibration for On-Chip Real-Time DNA Detection.IEEE Transactions on Biomedical Circuits and Systems. 2018 Apr;12(2):390-401.
ProtonDx is a health technology business with global ambitions to help the world test for many pathogens including COVID-19 and influenza.
In July 2021 we have secured a funding round, and we are now looking for talented, energetic and ambitious professionals to join our team.
ProtonDx offers the opportunity to work with world-class innovation and creativity in a fast-growing and motivational environment.
We are growing, therefore new opportunities are likely to appear on this page frequently – please check back to find a role that suits you. Alternatively, if you would like to be considered for our future opportunities, please send a covering letter and CV to firstname.lastname@example.org
ProtonDx is a rare opportunity to make a positive impact in the world – if that appeals to you, we are keen to hear from you!